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Abstract 
Background: Glioblastomas are the most aggressive brain tumors with extremely poor prognosis despite advances 
in treatment techniques. MiR-10b is highly expressed in glioblastoma and regulates cell proliferation, migration and 
invasion. Here, we examined the role of MiR-10b on radiotherapy of glioblastomas.
Methods: MiR-10b mimic or anti-MiR-10b inhibitor was transfected in glioblastoma cells. WST-1 assay was used to 
examine the effect of MiR-10b on proliferation of transfected glioblastoma cells after radiation treatment. Apoptosis 
was examined by caspase 3/7 activity and TUNEL assay. The western blot was used to evaluate protein expression.
Results: Altered expression of MiR-10b changed the radiation-induced inhibitory effect on proliferation of glioblas-
toma cells with dose-dependent manner. MiR-10b decreased radiation-induced apoptosis in glioblastoma cells by 
activation of caspase 3/7 and inhibition Bcl-2 expression. MiR-10b enhances migration and invasion of glioblastoma 
cells in presence of radiation. In addition, MiR-10b decreased the sensitivity of glioblastoma cells to radiotherapy by 
activation of p-AKT expression.
Conclusions: MiR-10b might be a potential biomarker to predict radiotherapy response and prognosis in 
glioblastomas.
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Background
Glioblastomas remains the most common malignant pri-
mary brain tumor in adults [1]. These tumors account 
for 17 % of all intracranial tumors and 55 % of astrocytic 
tumors with an estimated 12,120 new cases predicted in 
2016 [2]. Glioblastomas are highly aggressive glioma with 
median survival rate of less than 15  months and 5-year 
survival rate of less than 4  % and are characterized by 
rapid growth, invasion and angiogenesis [3]. Glioblasto-
mas arise from astrocytes, and contain a mix of cell types 
histologically, which makes the treatment difficult [4]. 
The most common symptoms in patients with glioblas-
tomas are caused by increased pressure in the brain, such 
as headache, nausea and vomiting [5]. Although progress 
in treatment techniques, including surgery, radiotherapy 
and chemotherapy, the median survival for patients with 
glioblastomas has only marginally changed [6]. There-
fore, it is critical to find out new molecular targets and 
approaches to treat this aggressive disease. Radiotherapy 
is the standard adjuvant treatment for glioblastoma to kill 
remaining tumor cells after surgical removal [7]. It is also 
used to treat unresectable tumors combined with chem-
otherapy. Recent studies have shown some agents may 
be used as radiosensitizers or radiation modulators and 
enhance the efficacy of radiotherapy in tumor treatment 
[8].
MicroRNA expression profiling studies have revealed 
that numerous microRNAs (MiRNAs) are associated 
with glioblastoma tumorigenesis [9]. MiRNAs are short, 
non-coding RNA molecules and play important role in 
the regulation of gene expression by directly binding to 
target sites in the 3′-untranslated region of the targeted 
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mRNA. MiRNAs can function as either tumor suppres-
sors by targeting oncogenes or oncogenes by targeting 
tumor suppressors [10]. Recently, growing evidence has 
shown that MiR-10b is highly expressed in glioblastoma 
and could be a potential therapeutic target [11, 12]. MiR-
10b can promote cell cycle progression, migration and 
invasion of glioma cells [12, 13]. Further studies have 
demonstrated that MiR-10b regulates different gene 
expression and signaling pathways in heterogeneous cel-
lular environments [14].
Here, we examined the roles of MiR-10b in radio-
therapy of glioblastoma. We found that overexpression 
of miR-10b decreased the radiation-induced inhibitory 
effect on proliferation of glioblastoma cells, while down 
regulation of MiR-10b increased the radiation-induced 
inhibitory effect on proliferation of glioblastoma cells. 
Meanwhile, overexpression of MiR-10b inhibited radi-
ation-induced apoptosis, promoted migration and inva-
sion on glioblastoma cells by activation of AKT signaling. 
Our findings indicate that MiR-10b could be a poten-
tial biomarker to predict the radiotherapy response and 
prognosis in glioblastomas.
Results
MiR‑10b alters the radiation‑induced inhibitory effect 
on proliferation of glioblastoma cells
To examine the role of MiR-10b in the proliferation of 
glioblastoma cells, MiR-10b mimic or anti-MiR-10b 
inhibitor, and a random sequence MiRNA mimic mol-
ecule (used as a negative control) were separately trans-
fected into glioblastoma cells followed by different doses 
of ionizing radiation. WST-1 assay was used to evalu-
ate the proliferation of glioblastoma cells. As shown in 
Fig.  1a, b, the MiR-10b expression level was shown in 
transfected glioblastoma cells by qRT-PCR. Overexpres-
sion of MiR-10b promotes proliferation of both A172 and 
LN229 cells in absence of ionizing radiation (Figs. 1c, 2a). 
When A172 and LN229 cells (transfected with MiR-10b 
mimic or a random sequence MiRNA mimic molecule) 
were treated with different doses of ionizing radiation 
(30, 50 and 100  Gy), MiR-10b decreased the radiation-
induced inhibitory effect on the proliferation of A172 and 
LN229 cells at dose dependent manner (Figs. 1d–f, 2b–
d). In contrast, down expression of MiR-10b decreased 
proliferation of both A172 and LN229 cells in absence of 
ionizing radiation (Figs. 1g, 2e). When A172 and LN229 
cells, transfected with anti-MiR-10b inhibitor or a ran-
dom sequence MiRNA mimic molecule, were treated 
with different doses of ionizing radiation (30, 50 and 
100 Gy), MiR-10b enhanced the radiation-induced inhib-
itory effect on the proliferation of A172 and LN229 cells 
at dose dependent manner (Figs. 1h–j, 2f–h). 
MiR‑10b inhibits radiation‑induced apoptosis 
in glioblastoma cells
We further examined the role of MiR-10b on radiation-
induced apoptosis in glioblastoma cells by checking 
caspase 3/7 activity, TUNEL and apoptotic related pro-
tein. MiR-10b inhibited the caspase 3/7 activity in glio-
blastoma cells at dose dependent manner (Fig.  3a, b). 
The percentage of TUNEL positive cells significantly 
decreased after overexpression of MiR-10b in A172 cells 
(Fig. 3c, d). MiR-10b changed the expression of Bax and 
Bcl-2 in A172 cells (Fig. 3e, f ).
MiR‑10b enhances migration and invasion in glioblastoma 
cells
To examine the role of MiR-10b on cell aggression after 
ionizing radiation, the Transwell migration and Matrigel 
invasion assays were performed to evaluate migration 
and invasion of glioblastoma cells. MiR-10b enhanced 
the migration and invasion of A172 cells (Fig. 4a–e) and 
LN229 cells (Fig. 4f–j) as compared to the negative con-
trol cells at 5 Gy of radiation. The migration and invasion 
of negative control cells without radiation treatment was 
used as a quality control.
MiR‑10b increases p‑AKT expression
We further examined the expression of p-AKT in A172 
cells by western blot. As shown in Fig.  5a, b, there is 
no change in the total AKT expression level after over-
expression of MiR-10b at 5  Gy of radiation. However, 
MiR-10b significantly increased p-AKT expression at 
5 Gy of radiation. To further examine the role of AKT in 
MiR-10b mediated radioresistance of glioblastoma cells, 
SignalSilence AKT siRNA (catalogue number: 6211, 
Cell Signaling Technology, USA) was used to inhibit the 
expression of AKT in glioblastoma cells, then the pro-
liferation of glioblastoma cells was examined by WST-1 
assay after 30  Gy of radiation. Interestingly, when the 
AKT was knockdown, there is no change in the prolifera-
tion of A172 and LN229 cells transfected with MiR-10b 
(See figure on next page.) 
Fig. 1 MiR-10b promotes the survival of glioblastoma cells following irradiation. a The MiR-10b expression level in glioblastoma cells transfected 
with MiR-10b mimic. b The MiR-10b expression level in glioblastoma cells transfected with anti-MiR-10b inhibitor. c–f The proliferation of A172 cells 
transfected with MiR-10b mimic or random sequence MiRNA mimic molecule after different doses of irradiation treatment. g–j The proliferation of 
A172 cells transfected with anti-MiR-10b inhibitor or random sequence MiRNA mimic molecule after different doses of irradiation treatment
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Fig. 2 MiR-10b promotes the survival of glioblastoma cells following irradiation. a–d The proliferation of LN229 cells transfected with MiR-10b 
mimic or random sequence MiRNA mimic molecule after different doses of irradiation treatment. e–h The proliferation of LN229 cells transfected 
with anti-MiR-10b inhibitor or random sequence MiRNA mimic molecule after different doses of irradiation treatment
Fig. 3 MiR-10b inhibits radiation-induced apoptosis in glioblastoma cancer cells. a, b The caspase-3/7 activity in A172 cells and LN229 cells either 
transfected with MiR-10b mimic or random sequence MiRNA mimic molecule. c, d The TUNEL positive A172 cells either transfected with MiR-10b 
mimic or random sequence MiRNA mimic molecule at 5 Gy of radiation. e, f The levels of apoptotic proteins in A172 cells either transfected with 
MiR-10b mimic or random sequence MiRNA mimic molecule at 5 Gy of radiation
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mimic or a random sequence MiRNA mimic molecule at 
30 Gy of radiation (Fig. 5c, d).
Discussion
Radiotherapy plays central role in the treatment of brain 
tumors [15]. In the past decades, the standard treatment 
for patients with glioblastomas has been surgery with 
adjuvant radiotherapy. Despite the advance in efficacy 
of radiotherapy, various new chemotherapy agents and 
targeted therapies, the survival of patients with glioblas-
tomas remains poor [16]. Meanwhile, the radiotherapy 
resistance is one of the reasons for the failure of treatment 
in glioblastoma. Although the underlying mechanism 
of radiotherapy resistance is poorly understood, recent 
studies have shown numerous biological processes alter 
the efficacy of radiation, such as factors and molecules 
in cell cycle, inactivation of tumor suppressor genes 
and activation of oncogenes [17, 18]. Growing evidence 
has demonstrated that the presence of glioma initiating 
cells (GICs) is associated with radiotherapy resistance 
[19–21]. The GICs process a faster rate of double-strand 
break repair caused by ionizing radiation by activation of 
the DNA damage response, a biological process regulated 
at the post-translational level. MiRNAs are also involved 
in DNA damage response by different mechanisms. For 
example, DNA damage activates PI3  K-like kinases, 
which triggers expression of some MiRNA [22]. MiR-10b 
has been reported to be highly expressed in many can-
cers. Altered expression of MiR-10b affects proliferation, 
migration and invasion of numerous cancer cells [23–25]. 
Preis et  al. reported that increased miR-10b expres-
sion was associated with resistance to chemotherapy 
Fig. 5 MiR-10b activates AKT in A172 cells. a Expression of AKT and p-AKT in A172 cells transfected with MiR-10b mimic after treated with irradia-
tion. b The graph indicates the AKT and p-AKT relative expression level. The proliferation of A172 cells (c) and LN229 cells (d) transfected with MiR-
10b mimic or random sequence MiRNA mimic molecule at 30 Gy of radiation after knockdown of AKT
(See figure on previous page.) 
Fig. 4 MiR-10b increases the migration and invasion of glioblastoma cells. The invasion of A172 cells (a–c) and LN229 cells (f–h) transfected with 
the MiR-10b mimic or random sequence MiRNA mimic molecule after 5 Gy of radiation. The graph indicates the migration of A172 cells (d) and 
LN229 cells (i) transfected with the MiR-10b mimic or random sequence MiRNA mimic molecule after 5 Gy of radiation. The migration of negative 
control cells without radiation treatment was used as a quality control. The graph indicates the invasion of A172 cells (e) and LN229 cells (j) trans-
fected with the MiR-10b mimic or random sequence MiRNA mimic molecule after 5 Gy of radiation. The invasion of negative control cells without 
radiation treatment was used as a quality control
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and radiation in pancreatic ductal adenocarcinoma cells 
[26]. In our study, we found that MiR-10b overexpres-
sion decreased the radiation-induced inhibitory effect in 
glioblastoma cells. These results extent the critical role of 
MiR-10b in glioblastoma cells.
Another reason that makes glioblastomas untreatable 
is due to their highly invasive activity. These tumors can 
infiltrate adjacent healthy brain and make it less possi-
ble to be fully resected during surgery. It has been dem-
onstrated that some growth factors mediate invasion of 
glioblastoma, such as transforming Growth Factor-beta 
(TGFβ). Liu et  al. found that TGFβ might induce MiR-
10b expression and involved in the TGFβ-mediated 
migration of brain tumor cells by targeting PTEN [27]. 
Here, our study showed that MiR-10b enhanced the 
migration and invasion of glioblastoma cells after ion-
izing radiation. These findings suggest that MiR-10b has 
essential functions in glioblastoma progression.
AKT regulates multiple biological processes such as 
apoptosis, cell proliferation and cell growth. AKT is a 
serine-threonine protein kinase, and phosphorylation at 
S473 [28] and T308 [29] activates AKT, which mediates 
the downstream responses including cell proliferation, 
apoptosis and metabolism [30]. Liu et al. [27] found that 
MiR-10b could suppress PTEN expression. Gabriely et al. 
[12] found that MiR-10b regulated apoptosis of glioma 
cells by targeting BCL2 signaling. Our results showed 
that MiR-10b increased p-AKT expression in both pres-
ence and absence of ionizing radiation. These results 
indicated that AKT signaling pathway might be involved 
in the regulation of MiR-10b on the proliferation and 
apoptosis of glioblastoma cells after ionizing radiation 
treatment. Further studies are needed to elucidate the 
underlying molecular mechanism.
Conclusion
MiR-10b plays critical role in the regulation of tumori-
genesis and malignant progression of glioblastoma. Our 
results indicate that MiR-10b might be a potential bio-




A172 and LN229, human glioblastoma cell lines were 
purchased from American Type Culture Collection 
(ATCC, USA). The tumor cells were cultured in Dubel-
cco’s modified Eagle’s medium (DMEM) (Invitrogen, 
USA) supplemented with 100  µg  ml−1 streptomycin, 
100  U  ml−1 penicillin and 10  % fetal bovine serum 
(Invitrogen, USA). The cells were grown at 37  °C in a 
humidified incubator with 5 % CO2. All cells used in our 
experiments were at 70–80 % confluence.
Cell transfection and MiRNA quantification
MiR-10b mimics or anti-miR-10b inhibitor (Cata-
logue numbers 4464066 and 4464084, respectively, Inv-
itrogen, USA) was transfected to glioblastoma cells 
using Lipofectamine 2000 (Invitrogen, USA) following 
the manufacturer’s instructions. A random sequence 
MiRNA mimic molecule was used as a negative control 
(mirVana™miRNA mimic, Ambion, USA). To examine 
MiR-10b expression after transfection, total RNA was 
extracted from the transfected cells, and then cDNA 
was synthesized using TaqMan MicroRNA reverse tran-
scription kit (ThermoFisher, USA) according the manu-
facturer’s instructions. The housekeeping gene GAPDH 
was used as the endogenous reference gene, and the PCR 
primer sequences [31] were 5′-ACCACAGTCCATGCC 
sATCAC-3′ and 5′-TCCACCACCCTGTTGCTGTA-3′.
Cell proliferation assay
Cell proliferation was analyzed by WST-1 assay (Roche, 
USA). Briefly, the transfected glioblastoma cells (includ-
ing MiR-10b mimics, anti-MiR-10b inhibitor and random 
sequence MiRNA mimic) were seeded to 96-well plates 
at density of 2 × 104 cells well−1 and cultured overnight. 
Then, different doses of ionizing radiation were used to 
treat the cells. Cells were continued to grow at 37  °C in 
a humidified incubator. Every 24  h of culture, 20  µl of 
WST-1 was added to each well and incubated for at least 
60 min at 37  °C. Then, the absorbance was measured at 
490 nm. All experiments were performed in triplicates.
Caspase 3/7 activity
The glioblastoma cells were seeded in 24-well plates at 
density of 2  ×  105 cells well−1 and cultured overnight. 
Different doses of ionizing radiation were used to treat 
cells. After 24  h of culture, the caspase 3/7 activity was 
examined using the Caspase-Glo3/7 assay kit (Promega, 
Madison, USA) following the manufacturer’s protocol. 
Briefly, 20 µl of Caspase-Glo reagent was added to each 
well, then cells were incubated for at least 8 h with gen-
tle shaking at room temperature. The luminescence value 
was measured using 1 min lag time and 0.5 s well−1 read 
time. All experiments were carried out in triplicates.
TUNEL assay
Cell apoptosis were evaluated using Click-iT® TUNEL 
Assay kit (Invitrogen, USA). Briefly, A172cells were 
seeded to 96-well plates at the density of 2  ×  104 cells 
well−1 and cultured overnight. Then, cells were treated 
with ionizing radiation (5  Gy). Following 24-h incuba-
tion, cells were fixed with 4 % paraformaldehyde in PBS 
at room temperature for 20  min. Then the cells were 
permeabilized with Triton X-100 for 20  min followed 
incubation with terminal deoxynucleotidyltransferase 
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reaction buffer for at least 10 min at room temperature. 
TUNEL reaction mixture was added to each well and 
continued to incubate for 1 h at 37 °C. Following washes 
with 3  % BSA in PBS for 2  min with gentle shaking, 
Click-iT reaction mixture was added and incubated for 
30 min at room temperature. Afterwards, the cell nuclei 
were counterstained using Hoechst 33342 for 15 min at 
room temperature. The positive nuclei were measured by 
counting the TUNEL-positive cells in eight different, ran-
dom fields of view each well.
Matrigel invasion assays
Cell migration and invasion was evaluated by Promega 
invasion assays as described before [32]. Briefly, trans-
fected A172 cells were treated with 5  Gy of ionizing 
radiation, seeded on the upper transwell insert with or 
without matrigel in DMEM without FBS. DMEM con-
taining 5 % FBS was added to the lower insert. After 18 h 
of culture, the invaded cells were stained by Diff-Quik 
stain after removal of the non-invaded cells with cotton 
swabs. The numbers of invaded cells were counted, and 
the percentage of migration and invasion was shown as 
a ratio of invaded cells over cells normalized on day 2 of 
growth curve.
Western blot assay
The A172 cells were lysed in ice-cold lysis buffer (50 mM 
Tris–HCl, pH 7.5, 0.1 % SDS, 150 mM NaCl, 0.5 % deoxy-
cholate, 1 % NP-40, and 1× protease inhibitors). Twenty 
microgram of protein lysates were loaded to the SDS-
PAGE gel and transferred to PVDF membranes (Sigma, 
USA). Antibody incubations were carried out in 5 % non-
fat dry milk in TBS-T buffer at 4  °C with primary anti-
bodies [Bcl-2 (catalogue number: 2872, dilution: 1:1000), 
Bax (catalogue number: 2774, dilution: 1:1000), AKT 
(catalogue number: 9272, dilution: 1:1000) and p-AKT 
(catalogue number: 9271, dilution: 1:1000) from Cell 
Signaling Technology, USA]. The immune signals were 
developed with the EasySee Western Blot Kit (Transgen, 
Shanghai).
Statistical analysis
Results were shown as mean ± standard deviation. SPSS 
program (version 11.0, IBM, USA) was used for statisti-
cal analyses using Student’s t test or ANOVA test. Differ-
ences are considered statistically significant if p < 0.05.
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